Commentary/Response to Damkier et al

Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70058. doi: 10.1002/pds.70058.

Authors

Liana Martirosyan^{1

2}, Maria Giovanna Satta³, Juan Garcia Burgos³, Ulla Wändel-Liminga^{1

4}, Sabine Straus^{1

2}

Affiliations

¹ Pharmacovigilance Risk Assessment Committee (PRAC), European Medicines Agency (EMA), Amsterdam, The Netherlands.
² Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
³ European Medicines Agency, Amsterdam, The Netherlands.
⁴ Medical Products Agency, Uppsala, Sweden.

PMID: 39628104
DOI: 10.1002/pds.70058

No abstract available